HBO for morbidity reduction in non drug-eluting stents
A single HBO treatment seems to significantly reduce the risk of occlusion.
Occlusion was reduced from 20% to 3% of patients treated with HBO. If non-drug eluting stents can be used in a greater number of cases significant cost savings will result.
The Trust proposes a multi-centre study which should show evidence in a relatively short time frame.